Bayer, Pfizer and Ipsen-backed cancer therapeutics developer Pyxis Oncology priced its shares at the top of its range.
US-based cancer therapy developer Pyxis Oncology secured $168m in an upsized initial public offering on Friday representing exits for pharmaceutical firms Bayer, Pfizer and Ipsen. The company issued 10.5 million shares on the Nasdaq Global Select Market priced at the top of its $14 to $16 range. They opened at $18.88 but crashed to $13.20…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.